Use of monoclonal antibodies to distinguish protein conformational isoforms

• US 7,932,043 B2
• Filed: 08/18/2003
• Issued: 04/26/2011
• Est. Priority Date: 10/10/2002
• Status: Active Grant

• Current Assignee: Heinrich-Heine-Universität Düsseldorf, Regents of the University of California (University of California)
• Original Assignee: The University of California At San Francisco
• Inventors: Korth, Carsten, Lingappa, Vishwanath R.
• Primary Examiner(s): Lucas; Zachariah
• Assistant Examiner(s): Horning; Michelle
• Application Number:
  US10/490,977
• Publication Number:
  US 20070281318A1
• Time in Patent Office: 2,808 Days
• Field of Search: None
• US Class Current: 435/7.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2872 against prion molecules, e.g. CD230
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

Methods of preparing monoclonal antibodies that differentially bind to a single conformer of a protein of interest are described. Passive immunization using these antibodies as well as use of conformer-specific antibodies as diagnostic reagents for the purpose of stratification of patient populations with regards to disease outcome, drug efficacy or drug sensitivity is also disclosed as well as active immunization with the protein conformer. In the screening techniques, detection can be for example by tissue immunostaining, western blotting or solution IP. A specific mab termed 7VC which shows conformation specificity to CtmPrP, a prion protein conformer that triggers neurodegeneration under specific assay conditions of pH and copper concentration, is described. A second specific antibody termed 19B10 shows conformation specificity for NtmPrP, a prion protein conformer that downregulates total PrP expression and effects cell differentiation.

Claims

1. A method of detecting prion disease in a sample, said method comprising:

contacting said sample with a diagnostically effective amount of the monoclonal antibody designated 7VC; and

determining whether said antibody binds specifically to any material in said sample under conditions whereby differential binding of said antibody to PrP isoforms associated with prion disease occurs, wherein antibody binding is indicative of prion disease.

2. The method according to claim 1, wherein said sample is a tissue or a bodily fluid.

3. The method according to claim 1, wherein said conditions comprise a concentration of Cu²⁺ ions in an amount that promotes said differential binding.

4. The method according to claim 3, wherein said concentration is about 1 μ

M to about 50 μ

M.

5. The method according to claim 1, wherein said conditions comprise a pH of about 7.8.